We read with interest the article of Booyens et al. discussing the risk of venous
thromboembolism (VTE) with hormonal replacement therapy (HRT) [
[1]
]. This article nicely summarized over 80 years of HRT development for the relief of
menopausal symptoms, but we observed some approximations which, in our opinion, need
to be highlighted.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- To clot, or not to clot: the dilemma of hormone treatment options for menopause.Thromb. Res. 2022; 218: 99-111https://doi.org/10.1016/j.thromres.2022.08.016
- Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.Expert. Rev. Clin. Pharmacol. 2022; 15: 121-137
- Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk.Semin. Thromb. Hemost. 2020; 46: 872-886
- Biomarkers, menopausal hormone therapy and risk of venous thrombosis: the Women's Health Initiative.Res. Pract. Thromb. Haemost. 2018; 2: 310-319
- Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC).Maturitas. 2021; 152: 69https://doi.org/10.1016/j.maturitas.2021.08.013
- Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.Clin. Chem. Lab. Med. 2020; 58: 294-305
- Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.Contraception. 2020; 102: 396-402
- Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.Br. J. Haematol. 2002; 119: 1017-1023
- Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1116-1121
- Low thrombin generation in users of a contraceptive containing estetrol and drospirenone.J. Clin. Endocrinol. Metab. 2022; (In press)https://doi.org/10.1210/clinem/dgac511
Article info
Publication history
Published online: September 15, 2022
Accepted:
September 12,
2022
Received in revised form:
September 8,
2022
Received:
September 6,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
